Genzyme asks FDA to expand clofarabine's use to adults

11/24/2008 | American City Business Journals

Genzyme submitted an application seeking FDA approval to market clofarabine to treat adults with acute myeloid leukemia. The biotech firm already sells the drug under the brand Clolar for relapsed and treatment-resistant patients between ages 1 and 21 who suffer from acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX